U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911944) titled 'Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation' on March 28.
Brief Summary: The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
The main questions it aims to answer are: Does donanemab reduce amyloid in the brain? Is donanemab safe and well-tolerated in people with Down syndrome? Researchers will compare donanemab to a placebo (a look-alike substance that contains no drug) to see if donanemab works to reduce levels of amyloid in the brain.
Participants in the study will be 35-50 y...